Why GLP-1 medications upset your stomach: one mechanism, many symptoms
The short answer: GLP-1 receptor agonists slow how quickly food leaves your stomach (delayed gastric emptying). That is not a malfunction — it is part of how these drugs work. By keeping food in the stomach longer and acting on appetite centers in the brain, they help you feel full sooner and eat less. The trade-off is that a slower-moving digestive tract produces predictable symptoms: early fullness, nausea, bloating, gas and burping, and shifts in bowel habits.
Nausea specifically appears to be driven mostly by the brain, not just the stomach. Animal studies show GLP-1 receptors in the central nervous system are involved in the nausea response, which is why nausea can occur even when measurable gastric-emptying delay is modest (Wharton et al., Diabetes Obes Metab 2021). Delayed emptying is a bigger contributor for shorter-acting agents; longer-acting weekly drugs appear to slow emptying less over time as the body adapts.
This is a class effect — it applies across semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide, and dulaglutide, and to compounded versions of these drugs as well. Compounded GLP-1s are not FDA-approved as finished products, but they contain the same active ingredients and carry the same gastrointestinal class effects.
The single most important pattern to understand: these symptoms are dose-dependent and cluster around dose increases. That is why prescribers titrate slowly, and why the standard advice when side effects are rough is to talk to your clinician about staying at your current dose longer rather than pushing higher.
How common are they, and how long do they last? (the trial numbers)
Here is what the largest data set shows. In the STEP 1–3 weight-management trials of semaglutide 2.4 mg (the Wegovy dose), pooled across 2,117 people, the most common gastrointestinal events versus placebo were nausea (44% vs 16%), diarrhea (30% vs 16%), vomiting (24% vs 6%), and constipation (24% vs 11%). These match the current FDA Wegovy prescribing information almost exactly.
The reassuring part is severity and duration. Across those trials, 99.5% of GI events were non-serious and 98.1% were mild-to-moderate. Prevalence of nausea, diarrhea and vomiting peaked at about week 20 — the tail end of dose escalation — and declined afterward. Individual episodes were short: median duration was about 8 days for nausea, 3 days for diarrhea, and 2 days for vomiting (Wharton et al., 2021).
Constipation is the exception worth flagging: it lasted longer (median ~47 days) and its prevalence plateaued around week 10. So while nausea tends to be the loud early symptom that fades, constipation is the quiet one that can linger and often needs steady, proactive management.
Overall, roughly 40–70% of people on a GLP-1 report some GI symptom — occasionally reported as high as 85% in obesity trials where doses are higher (multidisciplinary expert consensus, Nutrients 2022). But only about 4.3% of semaglutide-treated adults stopped the drug because of GI side effects, and most of those discontinuations happened during, not after, dose escalation.
Symptom-by-symptom: frequency, why it happens, and first steps
The table below pulls the FDA Wegovy label frequencies together with the trial-based typical duration, the mechanism, and the first-line self-care that clinicians and major medical centers commonly suggest. Frequencies are for semaglutide 2.4 mg; other GLP-1s differ somewhat (tirzepatide carries a similar or slightly higher nausea/diarrhea profile, shorter-acting agents more nausea, longer-acting agents relatively more diarrhea).
None of these steps replace your prescriber's guidance, and you should never start, stop, or change a dose on your own — but they are the low-risk, evidence-informed measures that show up consistently across the FDA labels, the expert consensus, and academic medical centers.
Managing nausea: smaller meals, lower fat, and the ginger question
The direct answer: eat smaller, slower, blander, lower-fat meals, stop eating at the first sign of fullness, and stay hydrated with non-carbonated fluids. High-fat, greasy, fried, and very sweet foods are the most common nausea triggers because fat further slows gastric emptying — exactly the mechanism already at play. Because these drugs make you full faster, large portions overwhelm an already-slowed stomach.
Practical measures repeatedly cited in the expert consensus (Nutrients 2022) and by weight-management clinicians: eat 4–6 small meals instead of 2–3 large ones, don't lie down right after eating, sip fluids between (not during) meals, and get gentle movement like a short post-meal walk. Cold or room-temperature foods with less odor are often better tolerated than hot, aromatic meals when nausea is active.
On ginger: it is one of the few food-based remedies with real evidence for nausea, though the data come from pregnancy and chemotherapy — not GLP-1 studies specifically. A systematic review of clinical trials found that divided doses totaling about 1,500 mg (1.5 g) of ginger per day helped relieve nausea (Anh et al., Nutrients 2020, PMID 30680163). Because ginger's half-life is short (~2 hours), spreading it across the day works better than a single dose. Ginger is a supplement, not an FDA-approved treatment — the FDA does not evaluate supplement efficacy — so treat it as a low-risk add-on and check with your clinician, especially if you take blood thinners.
If nausea is severe or you cannot keep fluids down, that is a conversation with your prescriber, who may slow your dose titration or prescribe an anti-nausea medication. Do not simply skip meals to avoid nausea — inadequate hydration and nutrition create their own problems.
Constipation relief: fiber, fluids, and movement
Constipation is the GLP-1 symptom most worth getting ahead of, because slowed gut motility means stool moves through more slowly and water gets reabsorbed, leaving it harder and drier. In the Wegovy trials it affected about 24% of people and was the longest-lasting GI symptom (Wharton et al., 2021).
The standard, low-risk measures are the classic constipation trio: gradually increase dietary fiber (fruits, vegetables, whole grains, legumes), drink more water, and move your body — regular physical activity stimulates the bowel. Increase fiber slowly and with plenty of fluid; ramping fiber up quickly without enough water can worsen bloating and gas, which are already elevated on these drugs.
If diet and hydration aren't enough, over-the-counter options such as an osmotic laxative (for example, polyethylene glycol) or a fiber supplement are commonly used, but confirm the choice with your pharmacist or clinician. A rare but serious concern the FDA notes in post-marketing reports is severe constipation progressing to fecal impaction or intestinal obstruction (ileus) — so constipation that is worsening, comes with a swollen abdomen and vomiting, or means you cannot pass gas or stool is a reason to seek care rather than reach for more laxatives.
Sulfur burps and eggy burps: what causes that rotten-egg smell
Sulfur burps are belches with a distinct rotten-egg odor, and they are a real, if less-discussed, GLP-1 side effect — 'eructation' (burping) is listed in the FDA labels and occurred in about 7% of Wegovy-treated adults versus under 1% on placebo. The smell comes from hydrogen sulfide (H2S) gas.
Here is the chain of events, as described by gastroenterologists and pharmacists (Drugs.com, Feb 2026; Inspira Health, 2025): the drug slows gastric emptying, so food — especially protein and sulfur-containing foods — sits in the stomach and upper gut longer. Gut bacteria ferment it, and breaking down sulfur-containing amino acids (like cysteine and methionine) releases hydrogen sulfide, which you then belch up. A shift in gut bacteria from slower transit can amplify it. Note this is largely an inferred mechanism; direct studies linking semaglutide specifically to sulfur burps are limited.
To reduce them: temporarily cut back on sulfur-rich foods (eggs, garlic, onions, cruciferous vegetables like broccoli, cauliflower and cabbage, and red meat), avoid carbonated drinks that add gas, eat smaller meals, chew thoroughly and slowly to swallow less air, and take a short walk after eating to keep things moving. You don't need to eliminate these nutritious foods permanently — a food-and-symptom diary helps you find your personal triggers, and a registered dietitian can help you cut triggers without sacrificing nutrition.
Some clinicians suggest short-term over-the-counter relief such as simethicone (an anti-gas agent) or bismuth subsalicylate (Pepto-Bismol), which can bind sulfur compounds — but bismuth isn't right for everyone (avoid with aspirin allergy, bleeding disorders, or certain kidney issues), so ask your pharmacist or clinician first. Importantly, sulfur burps do not mean the drug is or isn't working — their presence has no bearing on blood-sugar or weight results.
Diarrhea, bloating and gas: keeping it in check
Diarrhea affected about 30% of people in the Wegovy trials but individual episodes were brief (median ~3 days). Longer-acting weekly GLP-1s tend to cause relatively more diarrhea than shorter-acting ones, likely from their sustained effect on gut receptors. Bloating, gas (flatulence, ~6% vs 4% placebo), and mild reflux are also common as digestion slows.
For diarrhea, the priorities are staying hydrated and replacing fluids and electrolytes, eating bland, low-fat foods, and avoiding common irritants (very greasy foods, excess caffeine, alcohol, and sugar alcohols like sorbitol found in sugar-free products, which are a frequent hidden trigger). For gas and bloating, the same habits that help burping apply: smaller meals, slower eating, less carbonation, and light activity after meals.
If diarrhea is severe, bloody, or persistent, or you have signs of dehydration (dark urine, dizziness, marked thirst, reduced urination), contact your clinician rather than managing it at home.
When stomach symptoms signal something serious
Most GLP-1 stomach symptoms are uncomfortable but benign. A distinct set of red flags, however, are not routine and warrant prompt medical attention rather than waiting them out.
The most important is pancreatitis: severe, persistent abdominal pain — often in the upper abdomen and radiating to the back, frequently with nausea and vomiting. The FDA labels warn to discontinue the drug if pancreatitis is suspected. Gallbladder disease is another labeled warning; pain in the upper-right abdomen, fever, or yellowing of the skin or eyes (jaundice) needs evaluation.
Watch also for signs of a severely slowed or blocked gut. Vomiting undigested food hours after eating, early fullness with significant bloating, and persistent vomiting can suggest gastroparesis-like slowing — the Wegovy label states the drug is not recommended in people with severe gastroparesis. Post-marketing reports include ileus and intestinal obstruction; a swollen, hard abdomen with an inability to pass gas or stool is an emergency. Blood in vomit or stool (or black, tarry stools) and signs of dehydration also warrant urgent care.
One safety note specific to these drugs: because they delay gastric emptying, tell any clinician about your GLP-1 before surgery, endoscopy, or any procedure with anesthesia or deep sedation — retained stomach contents can raise aspiration risk, and the label now flags this. And the general rule throughout: don't start, stop, or change your dose on your own — the fix for rough side effects is usually a slower titration your prescriber manages, not quitting cold.